Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

PubWeight™: 2.18‹?› | Rank: Top 2%

🔗 View Article (PMC 3658176)

Published in Cancer Cell on April 15, 2013

Authors

Boris Engels1, Victor H Engelhard, John Sidney, Alessandro Sette, David C Binder, Rebecca B Liu, David M Kranz, Stephen C Meredith, Donald A Rowley, Hans Schreiber

Author Affiliations

1: Department of Pathology, Committee on Immunology and Committee on Cancer Biology, The University of Chicago, Chicago, IL 60637, USA. bengels@bsd.uchicago.edu

Associated clinical trials:

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | NCT02963090

Articles citing this

Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 1.44

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology (2013) 1.03

Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96

Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin Invest (2016) 0.92

Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89

Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res (2015) 0.88

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87

Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. J Immunol (2014) 0.87

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology (2016) 0.84

Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84

A peptide's perspective on antigen presentation to the immune system. Nat Chem Biol (2013) 0.84

TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 0.82

Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. Cancer Immunol Res (2015) 0.81

A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79

Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Leukemia (2014) 0.78

Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies. Sci Rep (2013) 0.78

Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78

It's the peptide-MHC affinity, stupid. Cancer Cell (2013) 0.78

Adoptive T-cell therapy to treat liver cancer: is the liver microenvironment key? Oncotarget (2013) 0.78

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77

Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/K(b) Transgenic Mice. Front Immunol (2016) 0.77

Going Pro to enhance T-cell immunogenicity: easy as π? Eur J Immunol (2013) 0.76

Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature (2017) 0.76

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med (2017) 0.75

Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. Cancer Immunol Res (2015) 0.75

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun (2017) 0.75

Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer. Oncoimmunology (2014) 0.75

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. Biomolecules (2016) 0.75

Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75

The making of a killer (T cell). Oncotarget (2017) 0.75

Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. Proc Natl Acad Sci U S A (2016) 0.75

Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7. PLoS One (2015) 0.75

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer (2017) 0.75

Tools to define the melanoma-associated immunopeptidome. Immunology (2017) 0.75

Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. Cancer Immunol Immunother (2017) 0.75

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use. PLoS One (2017) 0.75

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24

Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 5.11

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31

Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science (2009) 3.88

T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol (2004) 3.85

Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev (1992) 3.47

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45

T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 3.41

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15

Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity (2003) 3.04

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med (1997) 3.03

T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science (1994) 2.81

Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81

Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53

Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell (2003) 2.28

Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07

Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol (2007) 2.05

A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00

The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med (1992) 1.81

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71

Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc Natl Acad Sci U S A (1997) 1.67

Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) 1.60

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood (2011) 1.56

A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc Natl Acad Sci U S A (2002) 1.52

CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48

Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol (1997) 1.43

Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol (1996) 1.40

Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol (2010) 1.40

Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J Exp Med (2004) 1.38

A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med (1999) 1.36

Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol (2006) 1.36

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol (2010) 1.24

Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol (2009) 1.18

Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A (2012) 1.16

A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell (2011) 1.02

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med (2002) 0.96

Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95

On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bull Math Biol (1986) 0.92

CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J Immunol (1996) 0.91

Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res (2001) 0.90

Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol (2003) 0.88

Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides. J Biol Chem (2009) 0.87

In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J Immunol (2010) 0.84

Articles by these authors

The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40

Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33

The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07

Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43

Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64

A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol (2006) 4.52

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47

The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02

Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell (2013) 4.02

NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99

Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95

A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol (2006) 3.73

Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol (2008) 3.71

NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59

HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43

How a single T cell receptor recognizes both self and foreign MHC. Cell (2007) 3.20

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15

Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity (2003) 3.04

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01

The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00

Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99

NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol (2007) 2.92

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics (2005) 2.91

Supramolecular structure in full-length Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance. Biophys J (2002) 2.78

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A (2007) 2.67

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67

Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol (2004) 2.63

Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med (2006) 2.62

Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53

Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53

Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol (2008) 2.48

Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med (2010) 2.44

Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43

Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38

Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol (2008) 2.35

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32

ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26

Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol (2008) 2.25

Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18

Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A (2009) 2.15

Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res (2008) 2.14

TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol (2002) 2.12

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A (2005) 2.11

Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10

Immune epitope database analysis resource. Nucleic Acids Res (2012) 2.09

Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol (2008) 2.07

Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res (2008) 2.07

Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol (2007) 2.05

Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 2.02

The 2.5 Å structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity (2010) 2.02

A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99

A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 1.98

Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. J Immunol (2002) 1.97

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95

Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 1.93

Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J Virol (2002) 1.93

CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89

T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86

T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85